The impact of obesity on oesophageal acid exposure time on and off proton pump inhibitor therapy

S. L. Shah, B. E. Lacy, J. K. DiBaise, M. F. Vela, M. D. Crowell

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background Obesity is associated with increased oesophageal acid exposure time (AET) in patients with gastro-oesophageal reflux (GER), and may decrease the effects of proton pump inhibitors (PPIs). Aim To evaluate the effects of increased body mass on the ability of PPI therapy to decrease AET in patients with reflux symptoms. Methods Acid exposure time profiles collected from adult patients using wireless pH-metry while on or off PPI therapy was retrospectively reviewed. Patients were separated into five body mass index (BMI) categories as defined by the World Health Organization. A multivariable logistic regression evaluated the association between abnormal AET and BMI groups while controlling for age, gender and pH capsule placement methods. Results The study group comprised 968 patients with 336 (34.7%) studied on a PPI and 632 (65.3%) studied off PPI therapy. AET (total greater than 5.3%) was found more frequently in the overweight (67%) and obese classes (74-80%) compared to those who were normal weight (40%) while off acid-suppressing medications (P <0.001). No significant differences were found between these groups when studied on acid-suppressing medications, and the proportion of patients with abnormal AET across BMI classes was similar regardless of taking a PPI either once or twice daily. Conclusions This is the largest study to report on the relationship between BMI and oesophageal acid exposure time in patients with GER on and off PPI therapy. We conclude that obesity is related to increased acid exposure time, but with no significant difference in acid exposure time among different weight-based groups when taking a once or twice-daily PPI.

Original languageEnglish (US)
Pages (from-to)1093-1100
Number of pages8
JournalAlimentary Pharmacology and Therapeutics
Volume42
Issue number9
DOIs
StatePublished - Nov 1 2015

Fingerprint

Proton Pump Inhibitors
Obesity
Acids
Body Mass Index
Therapeutics
Gastroesophageal Reflux
Weights and Measures
Capsules
Logistic Models

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

The impact of obesity on oesophageal acid exposure time on and off proton pump inhibitor therapy. / Shah, S. L.; Lacy, B. E.; DiBaise, J. K.; Vela, M. F.; Crowell, M. D.

In: Alimentary Pharmacology and Therapeutics, Vol. 42, No. 9, 01.11.2015, p. 1093-1100.

Research output: Contribution to journalArticle

Shah, S. L. ; Lacy, B. E. ; DiBaise, J. K. ; Vela, M. F. ; Crowell, M. D. / The impact of obesity on oesophageal acid exposure time on and off proton pump inhibitor therapy. In: Alimentary Pharmacology and Therapeutics. 2015 ; Vol. 42, No. 9. pp. 1093-1100.
@article{246b4b25e00c4b269d513c607c731be9,
title = "The impact of obesity on oesophageal acid exposure time on and off proton pump inhibitor therapy",
abstract = "Background Obesity is associated with increased oesophageal acid exposure time (AET) in patients with gastro-oesophageal reflux (GER), and may decrease the effects of proton pump inhibitors (PPIs). Aim To evaluate the effects of increased body mass on the ability of PPI therapy to decrease AET in patients with reflux symptoms. Methods Acid exposure time profiles collected from adult patients using wireless pH-metry while on or off PPI therapy was retrospectively reviewed. Patients were separated into five body mass index (BMI) categories as defined by the World Health Organization. A multivariable logistic regression evaluated the association between abnormal AET and BMI groups while controlling for age, gender and pH capsule placement methods. Results The study group comprised 968 patients with 336 (34.7{\%}) studied on a PPI and 632 (65.3{\%}) studied off PPI therapy. AET (total greater than 5.3{\%}) was found more frequently in the overweight (67{\%}) and obese classes (74-80{\%}) compared to those who were normal weight (40{\%}) while off acid-suppressing medications (P <0.001). No significant differences were found between these groups when studied on acid-suppressing medications, and the proportion of patients with abnormal AET across BMI classes was similar regardless of taking a PPI either once or twice daily. Conclusions This is the largest study to report on the relationship between BMI and oesophageal acid exposure time in patients with GER on and off PPI therapy. We conclude that obesity is related to increased acid exposure time, but with no significant difference in acid exposure time among different weight-based groups when taking a once or twice-daily PPI.",
author = "Shah, {S. L.} and Lacy, {B. E.} and DiBaise, {J. K.} and Vela, {M. F.} and Crowell, {M. D.}",
year = "2015",
month = "11",
day = "1",
doi = "10.1111/apt.13394",
language = "English (US)",
volume = "42",
pages = "1093--1100",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell",
number = "9",

}

TY - JOUR

T1 - The impact of obesity on oesophageal acid exposure time on and off proton pump inhibitor therapy

AU - Shah, S. L.

AU - Lacy, B. E.

AU - DiBaise, J. K.

AU - Vela, M. F.

AU - Crowell, M. D.

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Background Obesity is associated with increased oesophageal acid exposure time (AET) in patients with gastro-oesophageal reflux (GER), and may decrease the effects of proton pump inhibitors (PPIs). Aim To evaluate the effects of increased body mass on the ability of PPI therapy to decrease AET in patients with reflux symptoms. Methods Acid exposure time profiles collected from adult patients using wireless pH-metry while on or off PPI therapy was retrospectively reviewed. Patients were separated into five body mass index (BMI) categories as defined by the World Health Organization. A multivariable logistic regression evaluated the association between abnormal AET and BMI groups while controlling for age, gender and pH capsule placement methods. Results The study group comprised 968 patients with 336 (34.7%) studied on a PPI and 632 (65.3%) studied off PPI therapy. AET (total greater than 5.3%) was found more frequently in the overweight (67%) and obese classes (74-80%) compared to those who were normal weight (40%) while off acid-suppressing medications (P <0.001). No significant differences were found between these groups when studied on acid-suppressing medications, and the proportion of patients with abnormal AET across BMI classes was similar regardless of taking a PPI either once or twice daily. Conclusions This is the largest study to report on the relationship between BMI and oesophageal acid exposure time in patients with GER on and off PPI therapy. We conclude that obesity is related to increased acid exposure time, but with no significant difference in acid exposure time among different weight-based groups when taking a once or twice-daily PPI.

AB - Background Obesity is associated with increased oesophageal acid exposure time (AET) in patients with gastro-oesophageal reflux (GER), and may decrease the effects of proton pump inhibitors (PPIs). Aim To evaluate the effects of increased body mass on the ability of PPI therapy to decrease AET in patients with reflux symptoms. Methods Acid exposure time profiles collected from adult patients using wireless pH-metry while on or off PPI therapy was retrospectively reviewed. Patients were separated into five body mass index (BMI) categories as defined by the World Health Organization. A multivariable logistic regression evaluated the association between abnormal AET and BMI groups while controlling for age, gender and pH capsule placement methods. Results The study group comprised 968 patients with 336 (34.7%) studied on a PPI and 632 (65.3%) studied off PPI therapy. AET (total greater than 5.3%) was found more frequently in the overweight (67%) and obese classes (74-80%) compared to those who were normal weight (40%) while off acid-suppressing medications (P <0.001). No significant differences were found between these groups when studied on acid-suppressing medications, and the proportion of patients with abnormal AET across BMI classes was similar regardless of taking a PPI either once or twice daily. Conclusions This is the largest study to report on the relationship between BMI and oesophageal acid exposure time in patients with GER on and off PPI therapy. We conclude that obesity is related to increased acid exposure time, but with no significant difference in acid exposure time among different weight-based groups when taking a once or twice-daily PPI.

UR - http://www.scopus.com/inward/record.url?scp=84942989853&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942989853&partnerID=8YFLogxK

U2 - 10.1111/apt.13394

DO - 10.1111/apt.13394

M3 - Article

C2 - 26345151

AN - SCOPUS:84942989853

VL - 42

SP - 1093

EP - 1100

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 9

ER -